Skip to main content
. 2021 Jan 13;143(11):1109–1122. doi: 10.1161/CIRCULATIONAHA.120.049447

Figure 2.

Figure 2.

Incidence rates for major adverse cardiovascular events after month 4 according to ranges of low-density lipoprotein cholesterol achieved at month 4 in the alirocumab group and in propensity score–matched patients from the placebo group. ALI indicates alirocumab; ARR, absolute risk reduction; PBO, placebo; and PSM, propensity score-matched.